- Home
- NRC vs ERAS Comparison
NRC vs ERAS Comparison
Compare NRC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- ERAS
- Stock Information
- Founded
- NRC 1981
- ERAS 2018
- Country
- NRC United States
- ERAS United States
- Employees
- NRC N/A
- ERAS N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- NRC Health Care
- ERAS Health Care
- Exchange
- NRC Nasdaq
- ERAS Nasdaq
- Market Cap
- NRC 394.2M
- ERAS 448.1M
- IPO Year
- NRC N/A
- ERAS 2021
- Fundamental
- Price
- NRC $15.61
- ERAS $1.41
- Analyst Decision
- NRC
- ERAS Strong Buy
- Analyst Count
- NRC 0
- ERAS 5
- Target Price
- NRC N/A
- ERAS $5.70
- AVG Volume (30 Days)
- NRC 78.5K
- ERAS 1.3M
- Earning Date
- NRC 01-27-2025
- ERAS 03-26-2025
- Dividend Yield
- NRC 3.08%
- ERAS N/A
- EPS Growth
- NRC N/A
- ERAS N/A
- EPS
- NRC 1.04
- ERAS N/A
- Revenue
- NRC $143,060,000.00
- ERAS N/A
- Revenue This Year
- NRC N/A
- ERAS N/A
- Revenue Next Year
- NRC N/A
- ERAS N/A
- P/E Ratio
- NRC $15.01
- ERAS N/A
- Revenue Growth
- NRC N/A
- ERAS N/A
- 52 Week Low
- NRC $15.59
- ERAS $1.41
- 52 Week High
- NRC $42.00
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- NRC 35.77
- ERAS 25.44
- Support Level
- NRC $16.92
- ERAS $1.52
- Resistance Level
- NRC $18.41
- ERAS $1.76
- Average True Range (ATR)
- NRC 0.68
- ERAS 0.13
- MACD
- NRC -0.07
- ERAS 0.00
- Stochastic Oscillator
- NRC 0.73
- ERAS 0.00
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.